KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt RepaymentsNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShort-Term Debt issuances
Ratios

Astrazeneca (AZN) Receivables Refunds (2016 - 2025)

Historic Receivables Refunds for Astrazeneca (AZN) over the last 16 years, with Q4 2025 value amounting to $1.4 billion.

  • Astrazeneca's Receivables Refunds fell 2517.48% to $1.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.4 billion, marking a year-over-year decrease of 2517.48%. This contributed to the annual value of $1.4 billion for FY2025, which is 2517.48% down from last year.
  • Astrazeneca's Receivables Refunds amounted to $1.4 billion in Q4 2025, which was down 2517.48% from $1.2 billion recorded in Q3 2025.
  • Astrazeneca's Receivables Refunds' 5-year high stood at $1.9 billion during Q4 2024, with a 5-year trough of $347.0 million in Q1 2021.
  • Moreover, its 5-year median value for Receivables Refunds was $785.5 million (2022), whereas its average is $977.4 million.
  • Its Receivables Refunds has fluctuated over the past 5 years, first skyrocketed by 21637.24% in 2021, then plummeted by 3644.44% in 2025.
  • Over the past 5 years, Astrazeneca's Receivables Refunds (Quarter) stood at $663.0 million in 2021, then rose by 10.26% to $731.0 million in 2022, then skyrocketed by 95.08% to $1.4 billion in 2023, then soared by 30.36% to $1.9 billion in 2024, then dropped by 25.17% to $1.4 billion in 2025.
  • Its last three reported values are $1.4 billion in Q4 2025, $1.2 billion for Q3 2025, and $1.0 billion during Q2 2025.